NHS Rollout of MS Mobility Drug Raises Access Questions

NHS England has confirmed the rollout of fampridine, a licensed drug that improves walking speed in people with multiple sclerosis, but strict eligibility criteria mean only a fraction of the estimated 130,000 people living with MS in the UK will initially qualify. Officials said the drug will be prescribed through specialist neurology services rather than general practice, raising questions about equitable access across regions.

What Fampridine Does

Fampridine, also known as dalfampridine, is a potassium channel blocker that improves nerve signal conduction along damaged nerve fibres. Unlike disease-modifying therapies that target the underlying immune process in multiple sclerosis, fampridine addresses a specific symptom: reduced walking speed. According to the National Institute for Health and Care Excellence, the drug is not a cure and does not slow disease progression, but clinical trials have shown measurable improvements in mobility for a subset of patients.

Clinical Trial Data

Two pivotal phase III trials, published in The Lancet Neurology, found that around 35% to 43% of patients receiving fampridine showed a consistent improvement in walking speed, compared with roughly 9% to 12% on placebo. The improvement was measured using the Timed 25-Foot Walk test, a standard clinical assessment. Response was not universal — the majority of patients did not show a measurable benefit, which is why NICE has recommended a trial period before continued prescribing.

Eligibility and Access Restrictions

NHS commissioning guidance restricts fampridine prescriptions to adults with MS who have an Expanded Disability Status Scale score between 4 and 7, meaning they require some assistance to walk but retain limited independent mobility. Patients with severe kidney impairment or a history of seizures are excluded, as the drug can lower the seizure threshold, according to the NHS.

Regional Variation in Specialist Access

Because prescribing is restricted to neurology specialists, patients in areas with fewer MS clinics may face longer waits for assessment. This mirrors broader concerns raised in coverage of NHS GP Surgery Closures at Record High — Millions Lose Access to Local Doctor, where reduced local access to primary care has pushed more diagnostic and referral work onto already stretched specialist services. MS Society representatives have said they will monitor whether uptake differs significantly between NHS trusts.

Cost and Negotiation Context

The list price of fampridine has been a point of discussion during NHS budget planning, with officials weighing its cost against modest but meaningful quality-of-life gains for responders. This follows a pattern seen in other recent drug approvals, including negotiations detailed in NHS faces critical drug price negotiations with pharma firms, where manufacturers and NHS bodies have clashed over pricing before reaching confidential discount agreements.

Comparisons With Other Conditional Approvals

The stepped, trial-based prescribing model for fampridine echoes strategies used elsewhere in the health service to manage high-cost drugs with variable individual response. Similar frameworks have been applied in oncology, as seen in NHS Cancer Drugs Access Scheme Expands Amid Cost Pressures, and in the broader expansion of treatment pathways covered in NHS Cancer Treatment Access Widens as New Drug Approval Eases Backlog. Health economists say this "test and continue" approach helps the NHS avoid funding treatments for patients unlikely to benefit, though it adds administrative steps for clinicians and patients alike.

Patient Monitoring and Safety

The World Health Organization has not issued specific guidance on fampridine, as it falls under national regulatory authority rather than global public health emergency frameworks. However, WHO's general principles on rational medicine use — matching treatment to demonstrated patient benefit — are reflected in the NHS's reassessment protocol. The British Medical Journal has previously published analyses noting that symptom-targeted MS therapies require careful monitoring for side effects including dizziness, insomnia and, in rare cases, seizures.

Symptoms and Monitoring Checklist

Clinicians overseeing fampridine treatment are advised to monitor patients for the following during the initial trial period:

• Change in walking speed or distance over the 14-day trial window
• New or worsening dizziness, particularly during the first week
• Sleep disturbances or insomnia
• Signs of urinary tract infection, which can reduce drug effectiveness
• Any history of seizure activity, which requires immediate discontinuation
• Kidney function, especially in patients with pre-existing renal impairment

Wider Implications for MS Care

Multiple sclerosis charities have broadly welcomed the approval while cautioning that mobility aids, physiotherapy and disease-modifying drugs remain essential components of comprehensive care. The NHS has stressed that fampridine is intended as an addition to, not a replacement for, existing MS management plans. Comparisons have also been drawn with other recent NHS therapeutic rollouts aimed at specific patient subgroups, such as the approach outlined in NHS Launches Drug to Delay Type 1 Diabetes Onset, which similarly targets a narrowly defined population based on measurable clinical criteria.

What Patients Should Ask Their Clinician

• Whether their current EDSS score meets NHS eligibility thresholds
• How the 14-day trial and walking speed assessment will be conducted
• What side effects should prompt an early consultation
• Whether local neurology services have capacity for timely assessment
• How fampridine interacts with existing MS medications

The rollout represents a targeted, evidence-based addition to the NHS's MS treatment options rather than a broad solution for all patients. As specialist services absorb the additional prescribing and monitoring workload, health officials say access consistency across England will be closely watched in the coming months, with formal review data expected to inform future NICE guidance updates.